|Abiraterone in metastatic prostate cancer without previous chemotherapy|
CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ...
New England Journal of Medicine 368 (2), 138-148, 2013
|Adjuvant therapy for completely resected stage II colon cancer|
A Figueredo, ME Coombes, S Mukherjee
Cochrane Database of Systematic Reviews, 2008
|Breast cancer chemotherapy induces the release of cell‐free DNA, a novel procoagulant stimulus|
LL Swystun, S Mukherjee, PC Liaw
Journal of Thrombosis and Haemostasis 9 (11), 2313-2321, 2011
|Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial|
PJ Goodwin, RJ Segal, M Vallis, JA Ligibel, GR Pond, A Robidoux, ...
Journal of clinical oncology 32 (21), 2231-2239, 2014
|Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate …|
F Saad, S Hotte, S North, B Eigl, K Chi, P Czaykowski, L Wood, M Pollak, ...
Clinical Cancer Research 17 (17), 5765-5773, 2011
|External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative …|
TJ Whelan, JA Julian, TS Berrang, DH Kim, I Germain, AM Nichol, M Akra, ...
The Lancet 394 (10215), 2165-2172, 2019
|Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study|
YJ Ko, CM Canil, SD Mukherjee, E Winquist, C Elser, A Eisen, ...
The lancet oncology 14 (8), 769-776, 2013
|Effect of metformin vs placebo on weight and metabolic factors in NCIC CTG MA. 32|
PJ Goodwin, WR Parulekar, KA Gelmon, LE Shepherd, JA Ligibel, ...
JNCI: Journal of the National Cancer Institute 107 (3), 2015
|A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium|
SS Sridhar, E Winquist, A Eisen, SJ Hotte, E McWhirter, IF Tannock, ...
Investigational new drugs 29 (5), 1045-1049, 2011
|A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer …|
KN Chi, EY Yu, C Jacobs, J Bazov, C Kollmannsberger, CS Higano, ...
Annals of Oncology 27 (6), 1116-1122, 2016
|Is red meat intake a risk factor for breast cancer among premenopausal women?|
VH Taylor, M Misra, SD Mukherjee
Breast cancer research and treatment 117 (1), 1-8, 2009
|Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label …|
KN Chi, CS Higano, B Blumenstein, JM Ferrero, J Reeves, S Feyerabend, ...
The lancet oncology 18 (4), 473-485, 2017
|Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate|
G Attard, JS De Bono, CJ Logothetis, K Fizazi, SD Mukherjee, AM Joshua, ...
Clinical cancer research 21 (7), 1621-1627, 2015
|Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area|
H Mir, M Alhussein, S Alrashidi, H Alzayer, A Alshatti, N Valettas, ...
Canadian Journal of Cardiology 34 (8), 1059-1068, 2018
|Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma …|
T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ...
The Lancet Oncology 21 (12), 1574-1588, 2020
|Physician‐related facilitators and barriers to patient involvement in treatment decision making in early stage breast cancer: perspectives of physicians and patients|
MA O’Brien, PM Ellis, TJ Whelan, C Charles, A Gafni, P Lovrics, ...
Health Expectations 16 (4), 373-384, 2013
|A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer|
EK Beardsley, SJ Hotte, S North, SL Ellard, E Winquist, ...
Investigational new drugs 30 (4), 1652-1659, 2012
|Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)|
P Moretto, L Wood, U Emmenegger, N Blais, SD Mukherjee, E Winquist, ...
Canadian Urological Association Journal 7 (1-2), E44, 2013
|Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium|
SS Sridhar, MJ Mackenzie, SJ Hotte, SD Mukherjee, C Kollmannsberger, ...
Journal of Clinical Oncology 26 (15_suppl), 5047-5047, 2008
|Tn-MUC1 DC vaccination of rhesus macaques and a phase I/II trial in patients with nonmetastatic castrate-resistant prostate cancer|
E Scheid, P Major, A Bergeron, OJ Finn, RD Salter, R Eady, ...
Cancer immunology research 4 (10), 881-892, 2016